04.08.2014 • News

Catalent Prices New York IPO at $20.50 per Share

US-based Catalent, which claims to be the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, is pricing its initial public offering of 42,500,000 shares of its common stock at $20.50 per share.

The shares began trading on the New York Stock Exchange on July 31, and the offering is expected to close on August 5, 2014. The company has granted the underwriters a 30-day option to purchase up to an additional 6,375,000 shares at the initial public offering price.

Catalent, which has its corporate headquarters in New Jersey, said it expects to receive net proceeds of around $822.7 million after deducting underwriting discounts and estimated offering expenses. It intends to use the proceeds to pay down debt.

Morgan Stanley, J.P. Morgan, BofA Merrill Lynch, Goldman, Sachs & Co., Jefferies and Deutsche Bank Securities are acting as joint bookrunning managers for the offering. Blackstone Capital Markets, Piper Jaffray, Raymond James, Wells Fargo Securities, William Blair and Evercore are acting as co-managers.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read